ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CYRX vs KURA // RETURN ON INVESTED CAPITAL (ROIC)

CryoPort Inc. (NASDAQ) VS. Kura Oncology Inc. (NASDAQ) • 15-METRIC TALLY: CYRX 6 — KURA 3
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: CYRX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYRX VS. KURA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CYRX KURA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 47.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -11.50% -35.00% +23.50 CYRX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -2.70% -7.53% +4.83 CYRX /fcf-yield <GO>
Operating Margin -20.90% -60.00% +39.10 CYRX /operating-margins <GO>
Net Profit Margin 44.40% -60.00% +104.40 CYRX /net-margins <GO>
Revenue Growth (YoY) 12.40% 25.20% -12.80 KURA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.33 0.20 +1.13 CYRX /balance-sheet <GO>
Piotroski F-Score Quality 5/9 4/9 +1.00 CYRX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.3 49.0 -0.70 KURA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 9.9x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $926.4M $939.4M -$13.1M KURA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CYRX REV KURA REV CYRX GROSS % KURA GROSS % CYRX FCF KURA FCF
FY 2025 $176.2M $67.5M 47.1% — -$25.0M -$70.7M
FY 2024 $156.8M $53.9M 44.4% — -$33.6M $133.8M
FY 2023 $168.7M $0 — — -$757.0K -$124.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYRX // BETA —
KURA // BETA —